Dyne Therapeutics (DYN) Gets a Buy Rating from JonesTrading

JonesTrading analyst Lina Kaminski reiterated a Buy rating on Dyne Therapeutics (DYN) today and set a price target of $45.00. The company’s shares closed last Tuesday at $17.66.

According to TipRanks.com, Kaminski is a 1-star analyst with an average return of -3.2% and a 41.7% success rate. Kaminski covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Catalyst Biosciences, and Krystal Biotech.

Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $40.33.

See today’s analyst top recommended stocks >>

Based on Dyne Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $28.65 million. In comparison, last year the company had a GAAP net loss of $5.87 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts